Analysts Offer Insights on Healthcare Companies: Abbott Laboratories (ABT) and Blueprint Medicines (BPMC)
Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Abbott Laboratories (ABT – Research Report) and Blueprint Medicines (BPMC – Research Report).
Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks.
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener.
Abbott Laboratories (ABT)
Barclays analyst Matt Miksic maintained a Buy rating on Abbott Laboratories today and set a price target of $159.00. The company’s shares closed last Wednesday at $129.70.
According to TipRanks.com, Miksic is a 5-star analyst with an average return of
Abbott Laboratories has an analyst consensus of Strong Buy, with a price target consensus of $140.06, implying a 8.0% upside from current levels. In a report issued on April 3, Wells Fargo also maintained a Buy rating on the stock with a $136.00 price target.
See Insiders’ Hot Stocks on TipRanks >>
Blueprint Medicines (BPMC)
In a report released today, Peter Lawson from Barclays maintained a Hold rating on Blueprint Medicines, with a price target of $105.00. The company’s shares closed last Wednesday at $82.11, close to its 52-week low of $80.68.
According to TipRanks.com, Lawson ‘s ranking currently consits of 0 on a 0-5 ranking scale, with an average return of
Currently, the analyst consensus on Blueprint Medicines is a Strong Buy with an average price target of $130.25.
Read More on ABT:
Disclaimer & DisclosureReport an Issue
- Abbott Laboratories Reports Strong Q1 2025 Results
- Abbott Laboratories: Strong Buy Rating Amid Robust Financial Performance and Growth Potential
- Abbott price target raised to $137 from $135 at Jefferies
- Nvidia, AMD see charges due to new China export rules: Morning Buzz
- Abbott Laboratories: Strong Organic Growth and Strategic Positioning Drive ‘Buy’ Rating
